DRKS00011159已完成3 期
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trial - Target
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 254
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with severe sepsis or septic shock
- •onset of severe sepsis or septic shock not longer than 24 hours prior
- •to randomization
- •Antimicrobial therapy with piperacillin planned or started
- •age =18 years
- •written informed consent of the patient or legal representative
排除标准
- •pregnant or breast-feeding women
- •anamnestic known hypersensitivity against beta-lactam antibiotics or another part of the investigational medicinal product
- •previous treatment with piperacillin (in combination with tazobactam) > 24 hours before randomization
- •participation in another interventional clinical trial
- •previous participation (TARGET)
- •limits of therapy or cessation
- •impaired liver function (Child-Pugh C)
- •life expectancy < 28 day due to accompanying illnesses
- •piperacillin-measurement impossible within 24 hours after randomization
研究者
相似试验
已完成
不适用
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
撤回
不适用
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000447954Royal Brisbane & Women's Hospital150
尚未招募
不适用
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.rheumatoid arthritisadalimumabtherapeutic drug monitoringNL-OMON29559ReumafondsReade, centrum voor revalidatie en reumatologie102
已完成
不适用
Study of blood level of lifesaving antibiotic meropenum in serious ICU patients in relation to blood level that kills bacteria.CTRI/2013/07/003850Tata Memorial Hospital25
尚未招募
不适用
Pharmacokinetics and Therapeutic Drug Monitoring of Intravenous Sulbactam in PediatricsPK parameters of sulbactam in pediatric patients with proven or suspected multidrug resistance A. baumannii infection receiving intravenous sulbactamSulbactam, TDM, pharmacokinetics, A. baumannnii, pediatricsTCTR20221114001Ratchadapisek Sompoch Research Fund62